0001209191-20-013276.txt : 20200226
0001209191-20-013276.hdr.sgml : 20200226
20200226202901
ACCESSION NUMBER: 0001209191-20-013276
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200224
FILED AS OF DATE: 20200226
DATE AS OF CHANGE: 20200226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sarena Francis Willard
CENTRAL INDEX KEY: 0001423786
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36070
FILM NUMBER: 20658028
MAIL ADDRESS:
STREET 1: C/O FIVE PRIME THERAPEUTICS, INC.
STREET 2: 2 CORPORATE DRIVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FIVE PRIME THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001175505
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 260038620
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 111 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-365-5600
MAIL ADDRESS:
STREET 1: 111 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: FIVE PRIME THERAPEUTICS INC
DATE OF NAME CHANGE: 20020613
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-24
0
0001175505
FIVE PRIME THERAPEUTICS, INC.
FPRX
0001423786
Sarena Francis Willard
111 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Strategy Officer
Common Stock
2020-02-24
4
A
0
15000
0.00
A
93178
D
Common Stock
2020-02-24
4
A
0
15000
0.00
A
108178
D
Common Stock
2020-02-25
4
F
0
1863
4.87
D
106315
D
Common Stock
2020-02-26
4
F
0
1304
4.83
D
105011
D
Employee Stock Option (right to buy)
5.25
2020-02-24
4
A
0
90000
0.00
A
2030-02-23
Common Stock
90000
90000
D
Employee Stock Option (right to buy)
5.25
2020-02-24
4
A
0
90000
0.00
A
2030-02-23
Common Stock
90000
90000
D
Represents a retention equity incentive award consisting of shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 24, 2021, 2022 and 2023, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date.
Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 24, 2021, 2022 and 2023, provided the reporting person provides services to the Company through each such date.
Represents a retention equity incentive award consisting of options to purchase shares of the Company's common stock. One-fourth (1/4) of the shares underlying this option will vest on February 24, 2021, and the remainder of the shares underlying this option vest at a rate of one forty-eighth (1/48) per month thereafter, provided the reporting person provides services to the Company through each such date.
The shares underlying the option vest at a rate of one forty-eighth (1/48) per month following February 24, 2020, provided the reporting person provides services to the Company through each such date.
/s/ Francis Sarena
2020-02-26